Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
about
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KITStructural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLGleevec inhibits beta-amyloid production but not Notch cleavageThe expanding role of immunopharmacology: IUPHAR Review 16Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiaSmall-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptorSmall Molecule Recognition of c-Src via the Imatinib-Binding ConformationCrystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG ConformationThe structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase ConformationsTargeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsCrystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide ClassA Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora AStructural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainStructural and Functional Analysis of G Protein-Coupled Receptor Kinase Inhibition by Paroxetine and a Rationally Designed AnalogMechanisms of drug resistance in kinases.Molecular dynamics and protein function.An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinaseA Src-like inactive conformation in the abl tyrosine kinase domainA novel quantitative kinase assay using bacterial surface display and flow cytometryEmerging Roles of SIRT1 in Cancer Drug ResistanceImatinib treatment causes substantial transcriptional changes in adult Schistosoma mansoni in vitro exhibiting pleiotropic effectsc-Src binds to the cancer drug Ruxolitinib with an active conformationMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionTowards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational DynamicsTwo distinct phosphorylation pathways have additive effects on Abl family kinase activationPharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plantscAMP-dependent protein kinase (PKA) complexes probed by complementary differential scanning fluorimetry and ion mobility-mass spectrometryIdentification of RIP1 kinase as a specific cellular target of necrostatinsA Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.Two-state dynamics of the SH3-SH2 tandem of Abl kinase and the allosteric role of the N-capEnhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitorsHierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.A research-inspired laboratory sequence investigating acquired drug resistance.Dynamic protein domains: identification, interdependence, and stability
P2860
Q21142738-05BB86AC-012B-434C-8D0D-AB944674958BQ24307789-A0D20152-35A1-416D-B5C0-E87AB238D059Q24318313-C7B30617-395C-4214-B875-201EAAF52A9FQ24651465-C870F268-7E68-4C1C-B55B-3EB1543063A4Q24683037-026DF6C5-AC7B-411A-AB72-611E0F3EEB45Q26801862-8CA69D1E-7BA1-4A53-8C4A-7A7D42D649EAQ27001584-7DD78C99-6173-485E-A715-CFFE8AB0500BQ27640723-8175783D-6319-443F-B88F-69477D846588Q27650906-88059523-BA23-4179-863F-FDC38F55F969Q27652602-1BA8D9C3-DA57-44BC-874C-4B563F5B6D34Q27652985-3F62D8BC-1AEC-447B-93C4-F40DC22AB3E8Q27653890-12B01B31-5BF2-4AA4-9D03-4F8727AA7848Q27654059-CA907EAF-6057-48FD-8CB7-30159686136EQ27658951-AF08B871-6A09-4815-B59B-6E3DABA812A5Q27667290-61D8DD55-3682-4F3C-B5F1-7F4A6AA01B9AQ27676768-EEB77B3E-0550-4C28-9CEF-FB20F0EC9A51Q27678454-9EA34C33-A085-4816-9752-FE52B2195013Q27680587-1DC2050F-3DD8-452C-A6EA-D6F2E2064904Q27692567-1BB94B07-C4AA-4440-ADAD-BBEE7B33706DQ28248486-B0DA2815-8E26-43D0-BBB4-5A3CAF1581A1Q28276857-B0047B76-6EE0-4E0E-A2AC-6F51B9B17740Q28469170-8C42D7DE-7CA1-449B-A41A-279FD1EBE631Q28535179-44E3BCC8-8463-4DF7-A151-893FB0F6ABF4Q28536892-E58F114A-2EED-415D-986D-CB9ED9F0D033Q28539623-B4199A07-B9C7-4B00-9036-0B5583EBC94FQ28542851-7314FD1F-FC97-4BBD-8053-9B530A556354Q28548366-14E36748-F2FD-40D9-8AA0-E98EC65B7F26Q28551159-5CF6F5AF-E133-409F-BE2A-525F58983C8AQ28585350-B6DE34C9-6F85-44F8-BE2D-59FF0E5D25B3Q28596537-AB8A76CF-45C6-4F2C-BAAC-5BE5479188DBQ28822154-5FA916ED-80D9-4285-AAD4-BC734A1D9B88Q29616006-A218DE3C-1764-47B9-9832-8731B2D27EFCQ30009284-1BC947F9-5C4A-4444-AD94-9C2FC3A321FDQ30009530-0C48D003-37DE-4FBF-BA70-4B2E1E662747Q30009582-8CF88C89-4A36-4E66-B20B-69EBBC2BB9D0Q30009947-FEE6A559-8EF5-4774-9AC5-BAE5D98E0058Q30157152-27A9B515-52A4-4099-86BF-74B81C0ABFFBQ30374671-C49D52B0-4F48-46FC-AA36-D1987E81AD38Q30402618-CD3CC6E9-7B6A-4643-99AC-54ADC2624849Q30477470-BE7A1415-5309-43A1-897F-A76DD7C36A4B
P2860
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@ast
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@en
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@nl
type
label
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@ast
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@en
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@nl
prefLabel
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@ast
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@en
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@nl
P2093
P3181
P1433
P1476
Crystal structures of the kina ...... D173955 and imatinib (STI-571)
@en
P2093
Bayard Clarkson
Bhushan Nagar
Darren R Veach
John Kuriyan
Patricia Pellicena
Thomas Schindler
W Todd Miller
William G Bornmann
P304
P3181
P407
P50
P577
2002-08-01T00:00:00Z